folfiri方案治疗老年结直肠癌安全性临床观察word格式论文.docxVIP

women. 19 patients were colonic cancer and 12 patients were rectal cancer. Their age ranged from 65 to 81 (68.6±3.9) years. There were 37 patients in the middle-aged group, including 20 men and 17 women. 22 patients were colonic cancer and 15 patients were rectal cancer. Their age ranged from 23 to 63 (47.4±10.9). All the cases received the chemotherapy of FOLFIRI regimen.The main grade Ⅲ/Ⅳ adverse reactions of the two groups were myelotoxicity and diarrhea. The differences between adverse reaction rates of the two groups were not significant (P0.05). 5 patients in the two groups, including 3 elder patients and 2 middle-aged patients, receive reduced doses about 30% because of the grade Ⅳ myelotoxicity, the symptom was relieved after adjusting, and no case was discontinued chemotherapy because of severe adverse events.The curative effect indicated that the response rate was 28.0% and disease control rate was 64.0% in the elderly group, the response rate was 31.0% and disease control rate was 58.6% in the middle-aged group. The efficacy of the two groups was similar. The difference between the two groups was not significant.There were 30 patients in the elderly group and 22 patients in the middle-aged group had the comorbidity. The common comorbidities in the elderly were hypertension and diabetic, while they were chronical gastritis，hepatitis b and cholelithiasis.The incidences of myelotoxicity increased (P=0.012) in the elderly group along with the increased score of MCIRS-G, while no differences were observed about the adverse reactions of the middle-aged group.Conclusion:FOLFIRI is a safe and effective regimen for the elderly patients with colorectal cancer, and the risk of toxicity was similar between the two groups. The incidences of myelotoxicity increased in the elderly group in paralled with the increased score of MCIRS-G.Key words: FOLFIRI Regimen/colorectal cancer/elderly/adverse reaction英文缩略词表英文缩写英文全称中文名MCIRS-GModified Cumulative Illness Rating-Geriatri